Today's tidings should ease patient enrollmentPatient enrollment is a big challenge for an upstart like Theralase. It's probably safe to assume that would-be TLT trial participants are presented with more than one trial option. The fact that we now have two patients with late-stage NMIBC who are cancer free after nine months, with virtually zero adverse side affects, borders on miraculous.
One can't help to believe that TLT's potentially industry-leading NMIBC treatment will become ever-increasingly attractive to would-be clinical trial participants.